Abstract: A method for identifying and analyzing dissolved organic nitrogen of different sources in wastewater includes extracting DON in wastewater to obtain a DON extract, detecting mass spectrum peaks in the DON extract, pre-processing the spectral data of the wastewater sample; constructing a network relationship of the substance reaction in the wastewater sample; screening the substance reaction relationship of DON; and determining different sources of DON.

Abstract: The present disclosure provides a method for screening, isolating and purifying analytes.

Abstract: A method of processing of a biological sample containing multiple metabolites is described The method comprising the steps of pre-treating the biological sample with a metabolite extraction solvent to provide a pre-treated sample, separating a first aliquot of the pretreated sample by reverse phase liquid chromatography (RPLC) to provide a first eluent containing resolved hydrophobic metabolites, and separating a second aliquot of the pre-treated sample by hydrophilic interaction liquid interaction chromatography (HILIC) to provide a second eluent containing resolved hydrophilic metabolites. The first and second eluents are assayed using targeted tandem mass spectroscopy operated in multiple reaction monitoring mode. Each liquid chromatography step (LC) is directly hyphenated with the tandem mass spectrometry (MS/MS) into a single LC-MS/MS analysis. The extraction solvent typically comprises methanol, isopropanol and an acetate buffer.

Abstract: The present invention relates to methods, devices and systems for associating consumable data with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system adjusts one or more steps of an assay protocol based on consumable data specific for that consumable. Various types of consumable data are described, as well as methods of using such data in the conduct of an assay by an assay system. The present invention also relates to consumables (e.g., kits and reagent containers), software, data deployable bundles, computer-readable media, loading carts, instruments, systems, and methods, for performing automated biological assays.

Abstract: A glycopeptide analyzer that performs a structural analysis on glycoforms of a glycoprotein, including: a spectrum creator creating an MS/MS spectrum for each elution time based on data acquired by an LC/MS analysis of a sample containing glycopeptides originating from a target glycoprotein; a peptide mass calculator selecting a glycopeptide-related spectrum from a plurality of MS/MS spectra and calculating the mass of a peptide from the selected spectrum; a similarity determiner determining a similarity between the glycopeptide-related spectrum and each of the other MS/MS spectra; an elution-time range estimator estimating an elution-time range based on a distribution of the frequency of occurrence of an MS/MS spectrum for which a high level of similarity has been determined on a time axis; and a glycan composition estimator selecting an ion peak corresponding to a mass equal to or greater than a peptide mass and estimating a glycan composition based on the peak.

Abstract: Disclosed are specifically a marker polypeptide of a Bothrops atrox-like thrombin and a method thereof for detecting species source and content of a snake venom-like thrombin and an application, relating to the technical field of snake venom detection. An amino acid sequence of the marker polypeptide is EAYNGLPAK (SEQ ID NO:1), and the marker polypeptide may be used to detect the species source and content of the snake venom-like thrombin in a sample. The marker polypeptide of the present disclosure may play an important role in characterizing the species source and content of the snake venom-like thrombin in the sample, and fill in the blank of a quality standard of snake venom of the Bothrops atrox.

Abstract: The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample. The in vitro method comprises the steps of obtaining a sample from a subject; contacting the sample with a cell; measuring cyclic adenosine monophosphate (cAMP) levels; and detecting the presence of neutralizing antibodies when cAMP levels are reduced relative to a negative control sample without neutralizing antibodies. An in vitro method of detecting the presence of neutralizing antibodies in a sample from a subject treated with Abaloparatide, is also provided. Further provided herein is a kit for carrying out the methods described herein comprising components required to carry out the obtaining, contacting, measuring and detecting steps and instructions for use.

Abstract: The present disclosure provides a method of treating cancer by immune checkpoint blockade, or selecting patients for treatment with immune checkpoint blockers, by detecting tumors with high levels of T-lymphocytes with low levels of activation and proliferation. In various embodiments the tissue sample may be from a conventional biopsy. In various embodiments the cancer may be non-small cell lung cancer.

Abstract: An apparatus for capturing a target analyte in advance of performing spectroscopic analysis to determine the existence of the target analyte from a source contacted with a collection substrate. The collection substrate is fabricated of a material selected to have an affinity for the target analyte, sufficiently transparent in a spectral region of interest and capable of immobilizing the target analyte thereon in a manner that limits scattering sufficient to obscure spectral analysis. The collection substrate may be coated with a material selected to react with, bind to, or absorb the target analyte. The target analyte may be captured to the collection substrate by one or more of wiping, dabbing or swabbing a target analyte carrier with the collection substrate.

Abstract: Methods for product authentication, which include: providing an article having a substrate with an analyte encoded composition; obtaining a sample of the composition; applying the sample to a test device to obtain test results, analyzing test results from the test device using an electronic device communicatively connected to an authentication authority, wherein the electronic device transmits the test device code and the test results to the authentication authority and confirms or denies authentication after comparison to an authentication database of authentic test results.

Abstract: The present application is related to a method for identifying whether porcine heparin is adulterated with heparin from ruminants, comprising: (1) respectively detecting the contents of trisaccharide(4S) and ?UA2S-GlcNAc6S (?IA) in a sample and at least three batches of porcine heparin standards; (2) calculating a ratio of the trisaccharide(4S) to the ?IA as well as a standard deviation (SD) of the ratio in the porcine heparin standards; when the ratio of the trisaccharide(4S) to the ?IA in the sample exceeds a maximum value of the ratio in the porcine heparin standards+3SD, where the sample is considered to be mixed or adulterated with heparin from ruminants; wherein the detection method used is hydrophilic interaction liquid chromatography-mass spectrometry (HILIC-MS) or multiple reaction monitoring (MRM). The method can distinguish porcine heparin from ovine and bovine heparin based on the structural differences, regardless of the production process the heparin has undergone.

Abstract: Disclosed herein is the use of plasma osteopontin (OPN) levels for diagnosing and predicting the severity and outcomes in traumatic brain injury (TBI), such as adult and pediatric TBI. The disclosed method can be used to diagnose TBI in any subject, such as pediatric, adult, and geriatric subjects. However, the method is particularly useful in pediatric subjects where current methods are insufficient. A particularly useful advantage of the disclosed methods is the ability to diagnose Abusive Head Trauma (AHT) in a pediatric subject.

Abstract: Methods for identifying and detecting potential disease specific biomarkers from biofluids. The methods involve in vivo administration of nanoparticles to a subject in a diseased state or incubating nanoparticles in a biofluid sample taken from a subject in a diseased state and analysis of the biomolecule corona formed on said nanoparticles. The methods distinguish between a healthy and diseased state in a subject, such as, for example, the presence of a tumor in a human subject.

Abstract: Nanozymes capped with a radical-scavenging capping agent are disclosed for use in biosensing assays with improved sensitivity. The radical-scavenging capping agent facilitates the capture and retention of one or more radicals for enhancing a catalytic reaction. In some example embodiments, the nanozyme capped by the radical-scavenging capping agent is capable of catalyzing the decomposition of hydrogen peroxide or molecular oxygen. The capped nanozymes may be incorporated with an electrode, such as the working electrode of an electrochemical sensor, for achieving enhanced catalytic activity and a lower limit of detection. In some example embodiments, the radical-scavenging capping agent is or includes thiocyanate.

Abstract: The present disclosure relates to an in vivo fluorescent or radioactive probe represented by a compound of formula I which is capable of longitudinal imaging of inducible nitric oxide synthase (iNOS) expression in living cells and living animals on a real time basis. The probe of the present disclosure can exhibit specific and high affinity binding to the iNOS enzyme with reduced enzyme inhibitory property and also enables longitudinal monitoring of iNOS expression along with its activity or NO production in a same experimental subject throughout the progression of a physiological or disease process without employing separate subjects as controls and experimental. The present disclosure further provides a rapid and inexpensive real time method for visualizing iNOS expression and its activity in living cells and living animals precisely, conveniently and reversibly along with simultaneous in vivo imaging of its catalytic product, nitric oxide (NO) in live physiological settings.

Abstract: The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

Abstract: There are provided a urine testing apparatus and a urine testing method which can stabilize urine vitamins for several days and improve testing accuracy and convenience of a urine collection test of a subject. According to this urine testing apparatus, the inner wall surface of a urine collection storage container is coated with an aqueous citric acid solution or the like as a urine stabilizer. Alternatively, a dried or freeze-dried aqueous citric acid solution or the like as the urine stabilizer is stored in the urine collection storage container. On the other hand, according to the urine testing method of this invention, the aqueous citric acid solution or the like as the urine stabilizer is added to the collected urine sample, the vitamin concentration of at least 7 days after urine collection is stabilized to stabilize each urine vitamin for several days, thereby improving the convenience of the urine collection test of the subject.

Abstract: A sample may be prepared and then analyzed using a liquid chromatography with tandem mass spectrometry system to determine presence and concentration of herbicide(s) present in the sample. In some examples, the method involves providing a sample containing one or more herbicides and adding a base to the sample. The base may increase the pH of the sample to ?12, thereby hydrolyzing esters of the one or more herbicides. The method may further involve, subsequent to hydrolyzing the esters of the one or more herbicides, adding an acid to the sample so as to lower the pH of the sample to ?3. Once prepared, the sample can be injected into a liquid chromatography instrument to separate the herbicide molecules from other molecules present in the sample before being ionized and characterized by mass-to-charge ratio and relative abundance using one or more mass spectrometers.

Abstract: Techniques for real-time or substantially real-time peak detection are described. In one embodiment, for example, logic coupled to memory may be configured to receive data from at least one analytical instrument and perform processing or analysis on the received data. Moreover, the logic may be configured to determine, via one or more GPUs or CPUs (or both), one or more peaks based on the processing or the analysis of the received data and generate peak detection data based on the detected one or more peaks in real-time or substantially real-time. Other embodiments are described.

Abstract: A method for analyzing or detecting methimazole (“MTZ”) comprising contacting a sample suspected of containing MTZ with the dendrimer-stabilized silver nanoparticles and performing surface-enhanced Raman scattering (SERS). Graphene-dendrimer-stabilized silver nanoparticles (G-D-Ag).